Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.14 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:30 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

tong ren tang technologies-h (TGRNF) Snapshot

Open
--
Previous Close
$1.14
Day High
--
Day Low
--
52 Week High
05/27/14 - $1.40
52 Week Low
12/17/14 - $1.14
Market Cap
2.3B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
628.7M
EX-Date
06/12/15
P/E TM
--
Dividend
$0.14
Dividend Yield
1.76%
Current Stock Chart for TONG REN TANG TECHNOLOGIES-H (TGRNF)

Related News

No related news articles were found.

tong ren tang technologies-h (TGRNF) Related Businessweek News

No Related Businessweek News Found

tong ren tang technologies-h (TGRNF) Details

Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicines primarily in Mainland China and Hong Kong. It offers its products in the form of pills, tablets, granules, capsules, and liquid. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, foot care products, and healthcare products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in technological development and sale of biological products, Chinese and Western medicines, and cosmetics; and wholesale and retail sale of Chinese medicine and healthcare products. The company was incorporated in 2000 and is based in Beijing, the People’s Republic of China. Tong Ren Tang Technologies Co., Ltd. is a subsidiary of Beijing Tong Ren Tang Company Limited.

3,595 Employees
Last Reported Date: 04/14/15
Founded in 2000

tong ren tang technologies-h (TGRNF) Top Compensated Officers

General Manager and Executive Director
Total Annual Compensation: CNY2.0M
Executive Director
Total Annual Compensation: --
Chief Accountant and Executive Director
Total Annual Compensation: CNY728.0K
Chairman, Compliance Officer, Chairman of Nom...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

tong ren tang technologies-h (TGRNF) Key Developments

Tong Ren Tang Technologies Co. Ltd. Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2014

Tong Ren Tang Technologies Co. Ltd. announced audited consolidated earnings results for the year ended December 31, 2014. For the year, the company's profit before income tax was RMB 740.6 million compared with RMB 595.1 million a year ago. Net cash generated from operating activities was RMB 333.9 million compared with RMB 375.5 million a year ago. Purchase of property, plant and equipment was RMB 262.4 million compared with RMB 188.6 million a year ago.

Tong Ren Tang Technologies Co. Ltd. Proposes Amendment to the Articles of Association

Tong Ren Tang Technologies Co. Ltd. proposed amendment to the Articles of Association in relation to the business scope of the Company as follows: Article 10: Which originally reads as: "The business scope of the Company covers development of medical technology, technology consultancy and services; manufacturing and sale of Chinese medicine, biological preparations, Chinese herbs, pharmaceutical chemicals reagents, antibiotics, biochemical drugs, medical devices, food, healthcare food and commodity; e-commerce; export of self-produced products and related technology; manufacturing and import and export of raw and auxiliary materials, machinery and equipment and technology required by production; property lease business; general transportation of goods; business of joint venture, production cooperation, product processing with supplied materials and compensation trade; import and export of other commodities approved by the Ministry of Foreign Trade and Economic Cooperation (save for the projects without specific license); operating and acting as an agent in the import and export business of various commodities and technology(excluding the commodities and technology, the operation of which is restricted or the import or export of which is prohibited (merchandise catalog for import and export is not enclosed)) by the State; product processing with imported materials and 'three categories of processing and one category of compensation businesses'; re-export and counter trade. It is proposed to be amended as follows: The business scope of the Company shall be consistent with and subject to that as approved by the company registration authorities. The business scope of the Company covers development of medical technology, technology consultancy and services; manufacturing and sale of Chinese medicine, biological preparations, Chinese herbs, pharmaceutical chemicals reagents, chemical raw medicine, antibiotics, biochemical drugs, medical devices, food, dairy products, liquor (rice wine), healthcare food and commodity wholesale pre-packaged food; retail pre-packaged food; e-commerce; export of self-produced products and related technology; manufacturing and import and export of raw and auxiliary materials, machinery and equipment and technology required by production; property lease business; general transportation of goods; business of joint venture, production cooperation, product processing with supplied materials and compensation trade; import and export of other commodities approved by the Ministry of Foreign Trade and Economic Cooperation (save for the projects without specific license); operating and acting as an agent in the import and export business of various commodities and technology (excluding the commodities and technology, the operation of which is restricted or the import or export of which is prohibited (merchandise catalog for import and export is not enclosed)) by the State; product processing with imported materials and 'three categories of processing and one category of compensation businesses'; re-export and counter trade. The proposed amendment to the Articles of Association are subject to the approval of the Shareholders at the general meeting of the Company by way of a special resolution.

Tong Ren Tang Technologies Co. Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2014

Tong Ren Tang Technologies Co. Ltd. announced that on March 20, 2015, the Board proposed a final cash dividend in respect of the year ended December 31, 2014 of RMB 0.14 (including tax) per share based on the total share capital of 1,280,784,000 shares, amounting to a total of RMB 179,309,760, which is subject to the shareholders' approval at the annual general meeting to be held on June 9, 2015. The company has paid RMB 0.25 (including tax, based on the total share capital of 640,392,000 shares)) per ordinary share last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TGRNF:US $1.14 USD 0.00

TGRNF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TGRNF.
View Industry Companies
 

Industry Analysis

TGRNF

Industry Average

Valuation TGRNF Industry Range
Price/Earnings 30.2x
Price/Sales 4.2x
Price/Book 3.9x
Price/Cash Flow 30.2x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TONG REN TANG TECHNOLOGIES-H, please visit www.tongrentangkj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.